New Blood-Cleansing device could help those who Can't take iron pills
NCT ID NCT06781099
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small study tests a device called MEX-CD1 that removes excess iron from the blood during a special type of dialysis. It is for people with myelodysplastic syndrome or myelofibrosis who have iron overload from blood transfusions but cannot take standard chelation therapy. Each participant will receive three short dialysis sessions over one week and be followed for 90 days to see if the device is safe and works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MEX-CD1 device for extracorporeal iron chelation
What this could lead to
If it works, this could offer a new way to manage iron overload in people who cannot tolerate standard chelation pills or injections.
What could go wrong
This is a very small early feasibility study (13 people) with no control group. The device is experimental, and it is unknown if it will be safe or effective enough for routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Lyon Sud
RECRUITINGOullins-Pierre-Bénite, 69495, France
-
Hôpital Lyon Sud
RECRUITINGOullins-Pierre-Bénite, 69495, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••